BridgeBio presented ATTRibute-CM data at the ESC Congress 2025, demonstrating a statistically significant reduction in CVM risk.
2 reports, 1 independent
Updated Aug 30
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BridgeBio presented ATTRibute-CM data at the ESC Congress 2025, demonstrating a statistically significant reduction in CVM risk.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BridgeBio
company in Palo Alto, United States
-
European Society of Cardiology
non-profit knowledge-based professional association
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireAcoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension - Acoramidis demonstrated a significant reducti
- GlobeNewswireBridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio